Oncotelic Therapeutics CEO's Patent Portfolio and Drug Development Expertise Highlighted in Industry Feature

Oncotelic Therapeutics, Inc. (OTCQB: OTLC) has been featured in a NetworkNewsAudio release highlighting the company's innovative therapeutics pipeline and the expertise of its leadership. The audio press release titled "Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth" emphasizes the significant contributions of chair and CEO Dr. Vuong Trieu, who has filed more than 500 patent applications and holds 75 issued patents spanning oncology, immunotherapy, and nanomedicine.

Dr. Trieu's previous development work includes Abraxane, a nanotechnology-based formulation that transformed treatment for breast, lung, and pancreatic cancers, as well as advancing Cynviloq, a novel micellar paclitaxel therapy. This track record of successful drug development positions Oncotelic to advance pioneering therapies with strong market potential in the competitive oncology space. The company's clinical-stage focus on high-unmet-need cancers and rare pediatric indications represents an important advancement in targeted cancer treatment approaches.

Oncotelic Therapeutics maintains a robust portfolio of inventions through its CEO's extensive intellectual property contributions, with more than 150 patent applications filed and 39 issued U.S. patents specifically attributed to Dr. Trieu's work with the company. This intellectual property foundation provides the company with a competitive advantage in developing novel cancer treatments. Beyond its internal development programs, Oncotelic operates through strategic partnerships, including owning 45% of GMP Bio, a joint venture that is advancing its own pipeline of drug candidates under Dr. Trieu's leadership.

The company's news and updates are available through its dedicated newsroom at https://ibn.fm/OTLC, providing investors and stakeholders with ongoing information about development progress. The feature was distributed through InvestorWire, a specialized communications platform that is part of the Dynamic Brand Portfolio at IBN, which provides comprehensive distribution services including wire solutions, article syndication to 5,000+ outlets, and social media distribution to millions of followers. Additional information about InvestorWire's services can be found at https://www.InvestorWire.com, with full terms of use and disclaimers available at https://www.InvestorWire.com/Disclaimer.

The combination of Dr. Trieu's proven drug development expertise and the company's strategic approach to building a diverse therapeutics pipeline positions Oncotelic to potentially deliver meaningful advancements in cancer treatment. This development is particularly significant given the ongoing need for innovative approaches to treating complex cancers and rare pediatric conditions, areas where current treatment options remain limited for many patients.